T-type calcium channel enhancer SAK3 promotes dopamine and serotonin releases in the hippocampus in naive and amyloid precursor protein knock-in mice

T-type calcium channels in the brain mediate the pathophysiology of epilepsy, pain, and sleep. Recently, we developed a novel therapeutic candidate, SAK3 (ethyl 8'-methyl-2',4-dioxo-2-(piperidin-1-yl)-2'H-spiro[cyclopentane-1,3'-imidazo[1,2-a] pyridine]-2-ene-3-carboxylate), for Alzheimer’s disease (AD). The cognitive improvement by SAK3 is closely associated with enhanced acetylcholine (ACh) release in the hippocampus. Since monoamines such as dopamine (DA), noradrenaline (NA), and serotonin (5-HT) are also involved in hippocampus-dependent learning and psychomotor behaviors in mice, we investigated the effects of SAK3 on these monoamine releases in the mouse brain. Oral administration of SAK3 (0.5 mg/kg, p.o.) significantly promoted DA and 5-HT releases in the naive mouse hippocampal CA1 region but not in the medial prefrontal cortex (mPFC), while SAK3 did not affect NA release in either brain region. The T-type calcium channel-specific inhibitor, NNC 55–0396 (1 μM) significantly antagonized SAK3-enhanced DA and 5-HT releases in the hippocampus. Interestingly, the α7 nicotinic ACh receptor (nAChR) antagonist, methyllycaconitine (1 nM) significantly inhibited DA release, and the α4 nAChR antagonist, dihydro-β-erythroidine (100 μM) significantly blocked both DA and 5-HT releases following SAK3 (0.5 mg/kg, p.o.) administration in the hippocampus. SAK3 did not alter basal monoamine contents both in the mPFC and hippocampus. SAK3 (0.5 mg/kg, p.o.) administration also significantly elevated DA and 5-HT releases in the hippocampal CA1 region of amyloid-precursor protein (APP)NL-GF knock-in (KI) mice. Moreover, hippocampal DA and 5-HT contents were significantly decreased in APPNL-GF KI mice. Taken together, our data suggest that SAK3 promotes monoamine DA and 5-HT releases by enhancing the T-type calcium channel and nAChR in the mouse hippocampus.

[1]  P. Lory,et al.  Phosphorylation of the Cav3.2 T-type calcium channel directly regulates its gating properties , 2015, Proceedings of the National Academy of Sciences.

[2]  P. McGuire,et al.  Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis , 2011, Molecular Psychiatry.

[3]  A. Schömig,et al.  Nicotine-induced release of noradrenaline and neuropeptide Y in guinea-pig heart: role of calcium channels and protein kinase C , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  L. Janssen,et al.  N-Type Ca(2+) channels trigger release of excitatory and inhibitory neurotransmitter from nerve endings in canine bronchi. , 1999, The Journal of pharmacology and experimental therapeutics.

[5]  Sungkwon Chung,et al.  Voltage-operated Ca2+ channels regulate dopamine release from somata of dopamine neurons in the substantia nigra pars compacta. , 2008, Biochemical and biophysical research communications.

[6]  J. Bizon,et al.  Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment , 2015, Front. Aging Neurosci..

[7]  F. Bergquist,et al.  Influence of r-type (Cav2.3) and t-type (Cav3.1–3.3) antagonists on nigral somatodendritic dopamine release measured by microdialysis , 2003, Neuroscience.

[8]  P. Stemkowski,et al.  Identification of interleukin-1 beta as a key mediator in the upregulation of Cav3.2–USP5 interactions in the pain pathway , 2017, Molecular pain.

[9]  U. Kumar,et al.  Immunohistochemical localization of dopamine receptor subtypes (D1R–D5R) in Alzheimer's disease brain , 2007, Brain Research.

[10]  J. Li,et al.  T-type calcium channels, but not Cav3.2, in the peripheral sensory afferents are involved in acute itch in mice. , 2017, Biochemical and biophysical research communications.

[11]  T. Saido,et al.  New mouse model of Alzheimer's. , 2014, ACS chemical neuroscience.

[12]  K. Fukunaga,et al.  Pharmacological properties of SAK3, a novel T-type voltage-gated Ca2+ channel enhancer , 2017, Neuropharmacology.

[13]  H. Meltzer,et al.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens , 2014, Psychopharmacology.

[14]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[15]  A. Lajtha,et al.  The Effects of Cholinergic and Dopaminergic Antagonists on Nicotine-Induced Cerebral Neurotransmitter Changes , 2005, Neurochemical Research.

[16]  T. Watanabe,et al.  Involvement of P-type calcium channels in high potassium-elicited release of neurotransmitters from rat brain slices , 1995, Neuroscience.

[17]  R. Tampi,et al.  Efficacy and Tolerability of Antidepressants in the Treatment of Behavioral and Psychological Symptoms of Dementia, A Literature Review of Evidence , 2011, American journal of Alzheimer's disease and other dementias.

[18]  H. Kunugi,et al.  Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia , 2014, Front. Neurosci..

[19]  A. Lajtha,et al.  Locally Administered Low Nicotine-Induced Neurotransmitter Changes in Areas of Cognitive Function , 2005, Neurochemical Research.

[20]  T. Snutch,et al.  Low threshold T‐type calcium channels as targets for novel epilepsy treatments , 2014, British journal of clinical pharmacology.

[21]  A. Petersen,et al.  Serotonin Regulates the Firing of Principal Cells of the Subiculum by Inhibiting a T-type Ca2+ Current , 2017, Front. Cell. Neurosci..

[22]  H. Meltzer,et al.  The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. , 1999, Schizophrenia bulletin.

[23]  K. Sakimura,et al.  T-type calcium channel antagonists suppress tremor in two mouse models of essential tremor , 2010, Neuropharmacology.

[24]  M. Rice,et al.  Limited regulation of somatodendritic dopamine release by voltage‐sensitive Ca2+ channels contrasted with strong regulation of axonal dopamine release , 2006, Journal of neurochemistry.

[25]  M. Neal,et al.  Evidence for a Complex Influence of Nicotinic Acetylcholine Receptors on Hippocampal Serotonin Release , 2000, Journal of neurochemistry.

[26]  V. Crunelli,et al.  The many faces of T-type calcium channels , 2014, Pflügers Archiv - European Journal of Physiology.

[27]  P. Blier,et al.  Serotonin and beyond: therapeutics for major depression , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.

[28]  C. Cotman,et al.  Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production , 2014, Neurobiology of Aging.

[29]  K. Fukunaga,et al.  The T-type calcium channel enhancer SAK3 inhibits neuronal death following transient brain ischemia via nicotinic acetylcholine receptor stimulation , 2017, Neurochemistry International.

[30]  J. Aston,et al.  Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract , 2010, British Journal of Nutrition.

[31]  Jung-Ha Lee,et al.  Molecular characterization of a neuronal low-voltage-activated T-type calcium channel , 1998, Nature.

[32]  E. Paykel,et al.  The role of noradrenaline and selective noradrenaline reuptake inhibition in depression , 2002, European Neuropsychopharmacology.

[33]  Edmund M. Talley,et al.  Differential Distribution of Three Members of a Gene Family Encoding Low Voltage-Activated (T-Type) Calcium Channels , 1999, The Journal of Neuroscience.

[34]  W. Oertel,et al.  A concerted action of L- and T-type Ca2+ channels regulates locus coeruleus pacemaking , 2015, Molecular and Cellular Neuroscience.

[35]  G. Reynolds,et al.  Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study , 1992, Cellular and Molecular Neurobiology.

[36]  H. Zhuang,et al.  NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-Benzimidazol-2-yl)propyl]-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: A New Selective Inhibitor of T-Type Calcium Channels , 2004, Journal of Pharmacology and Experimental Therapeutics.

[37]  A. Lajtha,et al.  Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus , 1997, Neuroscience.

[38]  M. Koenigs,et al.  The Multifaceted Role of the Ventromedial Prefrontal Cortex in Emotion, Decision Making, Social Cognition, and Psychopathology , 2017, Biological Psychiatry.

[39]  Y. Ohizumi,et al.  Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice , 2014, Neuroscience.

[40]  A. Lajtha,et al.  Nicotine-induced monoamine neurotransmitter changes in the brain of young rats , 2008, Brain Research Bulletin.

[41]  J. O'Donnell,et al.  Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice , 2015, Scientific Reports.

[42]  K. Fukunaga,et al.  The Disease-modifying Drug Candidate, SAK3 Improves Cognitive Impairment and Inhibits Amyloid beta Deposition in App Knock-in Mice , 2018, Neuroscience.

[43]  S. DeKosky,et al.  Monoamine neurons in aging and Alzheimer's disease , 2005, Journal of Neural Transmission / General Section JNT.

[44]  Ling He,et al.  D5 receptor agonist 027075 promotes cognitive function recovery and neurogenesis in a Aβ1-42-induced mouse model , 2016, Neuropharmacology.

[45]  S. Itohara,et al.  Single APP knockin mouse models of Alzheimer’s disease , 2014 .

[46]  S. Hernández-López,et al.  Presynaptic α4β2 Nicotinic Acetylcholine Receptors Increase Glutamate Release and Serotonin Neuron Excitability in the Dorsal Raphe Nucleus , 2012, The Journal of Neuroscience.

[47]  J. Palacios,et al.  Decreased densities of dopamine D1 receptors in the putamen and hippocampus in senile dementia of the Alzheimer type , 1988, Brain Research.

[48]  Steven V. Fox,et al.  In Vitro Characterization of T-Type Calcium Channel Antagonist TTA-A2 and In Vivo Effects on Arousal in Mice , 2010, Journal of Pharmacology and Experimental Therapeutics.

[49]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[50]  John T. Williams,et al.  Cholinergic Interneurons Underlie Spontaneous Dopamine Release in Nucleus Accumbens , 2017, The Journal of Neuroscience.

[51]  W. Riedel,et al.  Monoamine depletion in psychiatric and healthy populations: review , 2003, Molecular Psychiatry.

[52]  Ling He,et al.  The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ1–42-induced cognitive impairment , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[53]  J. Rinne,et al.  Brain dopamine D-1 receptors in senile dementia , 1986, Journal of the Neurological Sciences.

[54]  M. Milovanovic,et al.  Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. , 2016, Journal of Alzheimer's disease : JAD.

[55]  K. Fukunaga,et al.  The T‐type voltage‐gated calcium channel as a molecular target of the novel cognitive enhancer ST101: enhancement of long‐term potentiation and CaMKII autophosphorylation in rat cortical slices , 2012, Journal of neurochemistry.

[56]  B. Pollock,et al.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer’s disease , 2007, Neuropsychiatric disease and treatment.

[57]  Zayd M. Khaliq,et al.  Dopamine Inhibition Differentially Controls Excitability of Substantia Nigra Dopamine Neuron Subpopulations through T-Type Calcium Channels , 2017, The Journal of Neuroscience.

[58]  K. Fukunaga,et al.  Pharmacological properties of SAK 3 , a novel T-type voltage-gated Ca 2 þ channel enhancer , 2017 .

[59]  J. Fadel,et al.  Stimulation of lateral hypothalamic glutamate and acetylcholine efflux by nicotine: implications for mechanisms of nicotine‐induced activation of orexin neurons , 2010, Journal of neurochemistry.

[60]  Jochen Roeper,et al.  Selective Coupling of T-Type Calcium Channels to SK Potassium Channels Prevents Intrinsic Bursting in Dopaminergic Midbrain Neurons , 2002, The Journal of Neuroscience.